View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
July 1, 2020

The dominance of Eylea is expected to persist in the foreseeable future

By Victoria Smith

Bayer/Regeneron’s Eylea (aflibercept) is a fusion protein utilised in the treatment of retinal diseases frequently exacerbated by choroidal neovascularisation, a process in which new blood vessels grow from over-expression of pro-angiogenic proteins such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).

Roche/Genentech also has a portfolio of anti-VEGF products used to treat ophthalmic indications. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU